<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34846265</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aspirin relieves the calcification of aortic smooth muscle cells by enhancing the heat shock response.</ArticleTitle>
        <Pagination>
          <StartPage>17</StartPage>
          <EndPage>24</EndPage>
          <MedlinePgn>17-24</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2021.2007268</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Vascular calcification is a major complication of chronic renal failure, which has been identified as an active process partly driven by osteogenic transition of vascular smooth muscle cells (VSMCs). Aspirin could prevent cardiomyocyte damage by inducing heat shock response.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study investigates the effect of aspirin on alleviating VSMC calcification.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">An <i>in vitro</i> VSMC calcification model was established by 10-day calcification induction in osteogenic medium. VSMCs were grouped as following: control group (normal medium), calcified group (osteogenic medium) and treated group (osteogenic medium with 1 or 4 mmol/L aspirin). VSMC calcification was evaluated by calcified nodules formation, intracellular calcium concentration and osteoblastic marker (OPN and Runx2) expression.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">After 10-day culture, the intracellular calcium concentration in calcified group was significantly higher than that in control group (1.16 ± 0.04 vs. 0.14 ± 0.01 μg/mg, <i>p</i> &lt; 0.01), but significantly reduced in 1 mmol/L aspirin treated group (0.74 ± 0.05 μg/mg, <i>p</i> &lt; 0.01), and 4 mmol/L aspirin treated group (0.93 ± 0.03 μg/mg, <i>p</i> &lt; 0.01). The elevated expression of OPN and Runx2 induced by osteogenic medium was significantly relieved after 1 or 4 mmol/L aspirin treatment. The expression of HSF1, HSP70 and HSP90 was decreased in calcification-induced VSMCs, but significantly increased after treatment of aspirin. Furthermore, inhibition of HSP70 (or HSP90) by small-molecule inhibitor or small interfering RNA could partially abolish the anti-calcification effect of aspirin, proved by the changes of intracellular calcium concentration and osteoblastic marker expression.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Aspirin could relieve the calcification of VSMCs partially through HSP70- or HSP90-mediated heat shock response. These findings expanded the understanding of aspirin pharmacology, and imply that local induction expression of HSPs might be a potential therapeutic strategy for the prevention and therapy of vascular calcification.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Quanquan</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0001-6704-6247</Identifier>
            <AffiliationInfo>
              <Affiliation>Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Institute of Cardiac Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Institute of Cardiac Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Institute of Cardiac Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Xiaogang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Guokun</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Surgery, Institute of Cardiac Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R16CO5Y76E</RegistryNumber>
          <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001011" MajorTopicYN="N">Aorta</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018841" MajorTopicYN="N">HSP90 Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018869" MajorTopicYN="N">Heat-Shock Response</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061205" MajorTopicYN="N">Vascular Calcification</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Vascular smooth muscle cells</Keyword>
        <Keyword MajorTopicYN="N">heat shock protein 70</Keyword>
        <Keyword MajorTopicYN="N">heat shock protein 90</Keyword>
        <Keyword MajorTopicYN="N">heat shock transcription factor 1</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>12</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34846265</ArticleId>
        <ArticleId IdType="pmc">PMC8635617</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2021.2007268</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barna J, Csermely P, Vellai T.. 
2018. Roles of heat shock factor 1 beyond the heat shock response. Cell Mol Life Sci. 75(16):2897–2916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29774376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M.. 
2009. HSP 70 and atherosclerosis—protector or activator?
Expert Opin Ther Targets. 13(3):307–317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19236153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrne RA, Colleran R.. 
2020. Aspirin for secondary prevention of cardiovascular disease. Lancet. 395(10235):1462–1463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32386577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandra S, Roy A, Patel DR, Pahan K.. 
2019. PPARα between aspirin and plaque clearance. J Alzheimers Dis. 71(2):389–397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8163018</ArticleId>
            <ArticleId IdType="pubmed">31424405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desborough MJR, Keeling DM.. 
2017. The aspirin story – from willow to wonder drug. Br J Haematol. 177(5):674–683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28106908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyle SM, Hoskins JR, Kravats AN, Heffner AL, Garikapati S, Wickner S.. 
2019. Intermolecular interactions between Hsp90 and Hsp70. J Mol Biol. 431(15):2729–2746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6599576</ArticleId>
            <ArticleId IdType="pubmed">31125567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM.. 
2018. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res. 114(4):590–600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5852633</ArticleId>
            <ArticleId IdType="pubmed">29514202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guigas B, Viollet B.. 
2016. Targeting AMPK: from ancient drugs to new small-molecule activators. Exp Suppl. 107:327–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27812986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, et al. . 
2012. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 336(6083):918–922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3399766</ArticleId>
            <ArticleId IdType="pubmed">22517326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hybiak J, Broniarek I, Kiryczyński G, Los LD, Rosik J, Machaj F, Sławiński H, Jankowska K, Urasińska E.. 
2020. Aspirin and its pleiotropic application. Eur J Pharmacol. 866:172762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31669590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karohl C, D'Marco Gascon L, Raggi P.. 
2011. Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol. 7(10):567–577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21862991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilic A, Mandal K.. 
2012. Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications. Autoimmune Dis. 2012:502813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3530228</ArticleId>
            <ArticleId IdType="pubmed">23304456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C.. 
2008. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med. 12(3):743–761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4401125</ArticleId>
            <ArticleId IdType="pubmed">18266962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SJ, Lee IK, Jeon JH.. 
2020. Vascular calcification-new insights into its mechanism. Int J Mol Sci. 21(8):2685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7216228</ArticleId>
            <ArticleId IdType="pubmed">32294899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loppnow H, Zhang L, Buerke M, Lautenschlager M, Chen L, Frister A, Schlitt A, Luther T, Song N, Hofmann B, et al. . 
2011. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med. 15(4):994–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3922683</ArticleId>
            <ArticleId IdType="pubmed">20158569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu TS, Lim K, Molostvov G, Yang YC, Yiao SY, Zehnder D, Hsiao LL.. 
2012. Induction of intracellular heat-shock protein 72 prevents the development of vascular smooth muscle cell calcification. Cardiovasc Res. 96(3):524–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22933322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta TA, Greenman J, Ettelaie C, Venkatasubramaniam A, Chetter IC, McCollum PT.. 
2005. Heat shock proteins in vascular disease—a review. Eur J Vasc Endovasc Surg. 29(4):395–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15749041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paloian NJ, Giachelli CM.. 
2014. A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol. 307(8):F891–F900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4200295</ArticleId>
            <ArticleId IdType="pubmed">25143458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patrono C, Rocca B.. 
2012. Aspirin and other COX-1 inhibitors. In: Gresele P, Born G, Patrono C, Page C, editors. Antiplatelet agents. Handbook of experimental pharmacology. Vol. 210. Berlin, Heidelberg: Springer; p. 137–164.</Citation>
        </Reference>
        <Reference>
          <Citation>Rocha-Singh KJ, Zeller T, Jaff MR.. 
2014. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 83(6):E212–E220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4262070</ArticleId>
            <ArticleId IdType="pubmed">24402839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanada F, Kanbara Y, Taniyama Y, Otsu R, Carracedo M, Ikeda-Iwabu Y, Muratsu J, Sugimoto K, Yamamoto K, Rakugi H, et al. . 
2016. Induction of angiogenesis by a type III phosphodiesterase inhibitor, cilostazol, through activation of peroxisome proliferator-activated receptor-γ and cAMP pathways in vascular cells. Arterioscler Thromb Vasc Biol. 36(3):545–552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26769045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sankaranarayanan R, Kumar DR, Altinoz MA, Bhat GJ.. 
2020. Mechanisms of colorectal cancer prevention by aspirin—a literature review and perspective on the role of COX-dependent and -independent pathways. Int J Mol Sci. 21(23):9018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7729916</ArticleId>
            <ArticleId IdType="pubmed">33260951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scharf RE.
2012. Drugs that affect platelet function. Semin Thromb Hemost. 38(8):865–883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23111864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skelin M, Javor E, Lucijanic M.. 
2019. Aspirin use and the risk of cancer. JAMA Oncol. 5(6):912–913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31046062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung JY, Choi HC.. 
2011. Aspirin-induced AMP-activated protein kinase activation regulates the proliferation of vascular smooth muscle cells from spontaneously hypertensive rats. Biochem Biophys Res Commun. 408(2):312–317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21514281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang GK, Li SH, Zhao ZM, Liu SX, Zhang GX, Yang F, Wang Y, Wu F, Zhao XX, Xu ZY.. 
2016. Inhibition of heat shock protein 90 improves pulmonary arteriole remodeling in pulmonary arterial hypertension. Oncotarget. 7(34):54263–54273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5342340</ArticleId>
            <ArticleId IdType="pubmed">27472464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisell J, Ohukainen P, Näpänkangas J, Ohlmeier S, Bergmann U, Peltonen T, Taskinen P, Ruskoaho H, Rysä J.. 
2019. Heat shock protein 90 is downregulated in calcific aortic valve disease. BMC Cardiovasc Disord. 19:306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6923932</ArticleId>
            <ArticleId IdType="pubmed">31856737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, et al. . 
2017. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 376(13):1211–1222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28316279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu D, Zhang M, Lu Y, Tang S, Kemper N, Hartung J, Bao E.. 
2016. Aspirin-induced heat stress resistance in chicken myocardial cells can be suppressed by BAPTA-AM in vitro. Cell Stress Chaperones. 21(5):817–827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5003798</ArticleId>
            <ArticleId IdType="pubmed">27262845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao Y, Watson AD, Ji S, Bostrom KI.. 
2009. Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix Gla protein. Circ Res. 105(6):575–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2779117</ArticleId>
            <ArticleId IdType="pubmed">19661459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Zhang K, Huang F, Feng W, Chen J, Zhang H, Wang J, Luo P, Huang H.. 
2018. Exosomes, the message transporters in vascular calcification. J Cell Mol Med. 22(9):4024–4033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6111818</ArticleId>
            <ArticleId IdType="pubmed">29892998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Qian Z, Zhu H, Tang S, Wu D, Zhang M, Kemper N, Hartung J, Bao E.. 
2016. HSP90 gene expression induced by aspirin is associated with damage remission in a chicken myocardial cell culture exposed to heat stress. Br Poult Sci. 57(4):462–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27088575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao AS, Zou D, Wang HH, Han X, Yang P, Huang N.. 
2019. Hydrogen sulphide-releasing aspirin enhances cell capabilities of anti-oxidative lesions and anti-inflammation. Med Gas Res. 9(3):145–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6779009</ArticleId>
            <ArticleId IdType="pubmed">31552879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z, Wang Y, Li S, Liu S, Liu Y, Yu Y, Yang F, Xu Z, Wang G.. 
2019. HSP90 inhibitor 17-DMAG effectively alleviated the progress of thoracic aortic dissection by suppressing smooth muscle cell phenotypic switch. Am J Transl Res. 11(1):509–518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6357309</ArticleId>
            <ArticleId IdType="pubmed">30788006</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
